Great Antibody to Identify Donor T cells Using CD45.1

Oncology
Johns Hopkins School of Medicine
Graduate Student

Overall

Quality of Results

Ease-of-Optimization

What do these ratings mean?
Write a Review

Company:

Biolegend

Product Name:

PerCP/Cy5.5 anti-mouse CD45.1 Antibody

Catalog Number:

110728

Our lab studies the role of mTOR signaling in CD8 T cell differentiation and function. In order to study this process, we perform a lot of adoptive transfer experiments of donor transgenic T cells (CD45.1 or others) into different CD90.2/CD45.2 WT B6 congenic hosts. In order to identify the donor T cells, we use CD45.1 to distinguish host versus donor especially in co adoptive studies of two donor cells into the same host. This marker is quite reliable since it separates quite well from the host but it is somewhat on the dimmer side. The PerCp Cy5.5 CD45.1 antibody fits nicely into certain panels since it's usually a dim channel compared to other brighter channels; however, this antibody is reliable although at a higher dilution. We were able to readily identify the donor cells using this antibody from the host cells.

Experimental Design and Results Summary

Applications

Flow Cytometry

Sample

Murine Splenocytes

Primary Incubation

1:300. 30 mins, 4 deg incubation

Blocking Agent

FC blocking in FACS buffer (2% FBS, .2% NaAzide/PBS)

Secondary Incubation

None

Tertiary Incubation

None

Detection

Flow cytometer

Results Summary

We are able to readily identify the donor T cells from the host based on CD45.1 expression with CD8. We further analyzed this population after identification.

DOI or PMID #

N/A

Additional Notes

N/A

Related Categories

Image Gallery

Summary

The Good

The signal was very strong but only when using a higher dilution.

The Bad

Higher dilution needed to obtain the isolated population since dimmer channel.

The Bottom Line

A reliable antibody for identifying CD45.1 donor T cells in adoptive transfer experiments.

Share your experience with other scientists. Write a Review! »

Join the discussion